Oncology

Meta-analysis Confirms Biosimilarity Between Bevacizumab Biosimilars, Avastin in NSCLC, Colorectal Cancer

November 12th 2022

By Deana Ferreri, PhD

Article

The efficacy and safety of bevacizumab biosimilars in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (CRC) is comparable with the reference product (Avastin) and each other, according to a meta-analysis.

Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market

November 9th 2022

By Skylar Jeremias

Article

Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.

AMCP Nexus Abstracts Investigate Adoption, Budget Impact of Biosimilars

November 8th 2022

By Skylar Jeremias

Article

Abstracts presented at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting explored the adoption of infliximab biosimilars, utilization patterns of bevacizumab biosimilars in ophthalmology and oncology settings, and the budget impact of transferring patients to a natalizumab biosimilar from the originator.

Overview of Trastuzumab Biosimilars in HER2-Positive Breast Cancer

October 29th 2022

By Deana Ferreri, PhD

Article

Authors of a systematic review summarized the results of 21 published studies on the efficacy, safety, and cost-benefit ratio of trastuzumab biosimilars in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Trastuzumab Biosimilar Found Safe, Effective in Pretreated HER2-Positive Breast Cancer

October 15th 2022

By Deana Ferreri, PhD

Article

A study from the Republic of Korea confirmed the safety and efficacy of Herzuma (CT-P16) in patients with heavily pretreated human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.

Dr Nabil Saba Shares His Hope for Future Opdivo, Keytruda Biosimilars

October 12th 2022

By Skylar Jeremias

Video

Nabil Saba, MD, a medical oncologist and immunotherapy specialist in the treatment of head and neck cancer at Emory Healthcare and the Winship Cancer Institute, explained how the eventual introduction of biosimilars for Opdivo (nivolumab) and Keytruda (pembrolizuamb) will help patients with head and neck cancer.

Eye on Pharma: 2 US Launches, an EMA Filing, and Denosumab Results

October 6th 2022

By Skylar Jeremias

Article

Recently, the US got 2 new biosimilars on the market, a bevacizumab and an interchangeable ranibizumab; Amneal Pharmaceuticals filed for marketing authorization in Europe; and Sandoz released positive results for a denosumab candidate.

Biosimilars Oncology Roundup for September 2022—Podcast Edition

October 2nd 2022

By Skylar Jeremias

Podcast

On this episode of Not So Different, we take a look at some of the big stories regarding oncology biosimilars throughout the month of September, including 2 FDA approvals, and the withdrawal of a European application.

Biosimilars Oncology Roundup: September 2022

October 1st 2022

By Skylar Jeremias

Article

In addition to our month-long series preparing for the 2023 introduction of adalimumab biosimilars, September featured a number of updates for oncology biosimilars, including 2 FDA approvals and the withdrawal of a European application.

FDA Approves Celltrion Biosimilar for Avastin, Vegzelma

September 30th 2022

By Skylar Jeremias

Article

Vegzelma became the fourth biosimilar referencing Avastin (bevacizumab) to be approved for use in the United States for several types of cancer.